8-K: FTC Challenges Surmodics Acquisition by GTCR, Citing Anti-Competitive Concerns

The FTC has filed a complaint to block the proposed acquisition of Surmodics by GTCR due to concerns about its potential impact on competition.

Summary

• The U.S. Federal Trade Commission (FTC) has filed a complaint to block the proposed merger between Surmodics, Inc. and an entity indirectly controlled by funds affiliated with GTCR LLC.
• The FTC's primary concern is that the merger could reduce competition in the market.
• Surmodics has announced that it intends to vigorously defend the case in court to complete the merger.
• The merger agreement, announced on May 29, 2024, involves GTCR acquiring all outstanding shares of Surmodics for $43.00 per share in cash, valuing the company at approximately $627 million.
• The transaction is financed through a combination of committed equity from GTCR and committed debt financing.
• Surmodics shareholders approved the merger at a special meeting held on August 13, 2024.
• Upon completion of the transaction, Surmodics would become a privately held company, and its stock would no longer be listed on the Nasdaq Global Select Market.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the FTC's challenge to the merger, creating uncertainty and potential financial risks for Surmodics.

Positives

• Surmodics believes the merger is pro-competitive and will bring value to all stakeholders.
• Surmodics intends to vigorously defend the case in court in order to complete the Merger.
• Surmodics shareholders will receive $43.00 per share in cash, for a total equity valuation of approximately $627 million.

Negatives

• The FTC's challenge introduces uncertainty and potential delays to the merger.
• The litigation could be costly and time-consuming for Surmodics.
• If the merger is terminated, Surmodics' stock price may decline significantly.
• The merger agreement may be terminated in circumstances requiring Surmodics to pay GTCR a termination fee.
• The announcement or pendency of the Merger and the litigation with the FTC may have negative effects on Surmodics and its business.

Risks

• The parties may not prevail in the pending litigation with the FTC.
• The merger may not be consummated within the anticipated time period, or at all.
• Other conditions to the consummation of the merger under the merger agreement may not be satisfied.
• All or part of GTCR's financing may not become available.
• The significant limitations on remedies contained in the merger agreement may limit or entirely prevent Surmodics from specifically enforcing GTCR's obligations under the merger agreement or recovering damages for any breach by GTCR.
• Surmodics' stock price may decline significantly if the Merger is not completed.
• Surmodics' business, operating results or stock price may suffer.
• Surmodics' current plans and operations may be disrupted.
• Surmodics' ability to retain or recruit key employees may be adversely affected.
• Surmodics' business relationships (including, customers, franchisees and suppliers) may be adversely affected.
• Surmodics' management's or employees' attention may be diverted from other important matters.
• The Merger and related transactions may involve unexpected costs, liabilities, or delays.

Future Outlook

The future outlook is uncertain due to the pending litigation with the FTC, and the company's ability to consummate the merger is subject to various risks and conditions.

Management Comments

• Surmodics respectfully disagrees with the FTC's decision and remains committed to completing the Merger.
• Surmodics remains confident in both its rationale for the Merger and the value it will bring to all stakeholders, including shareholders, customers and patients.
• We have worked constructively with the FTC over the last several months to secure regulatory approval for the Merger and are disappointed by its decision to initiate litigation, as the Merger is pro-competitive.
• Surmodics intends to vigorously defend this case in court in order to complete the Merger.

Industry Context

The FTC's challenge reflects increasing regulatory scrutiny of mergers and acquisitions, particularly in the healthcare sector, where concerns about market concentration and potential anti-competitive effects are prevalent.

Comparison to Industry Standards

• It is difficult to compare this situation directly to industry standards as each merger faces unique regulatory hurdles.
• However, the FTC's focus on potential anti-competitive effects is consistent with its approach to mergers in concentrated industries.
• Other medical device companies, such as Boston Scientific and Medtronic, have faced similar scrutiny in past acquisition attempts.

Legal Proceedings

• The U.S. Federal Trade Commission (FTC) filed a complaint in the United States District Court for the Northern District of Illinois seeking to enjoin the Merger.

Stakeholder Impact

• Shareholders face uncertainty regarding the completion of the merger and the potential impact on the stock price.
• Customers may experience disruptions if the merger is delayed or blocked.
• Employees may face uncertainty regarding their future employment with the company.
• The merger could impact the competitive landscape for suppliers and other industry participants.

Next Steps

• Surmodics will vigorously defend its case in court against the FTC.
• The company will continue to assess the situation and provide updates as appropriate.

Key Dates

Keywords

Surmodics, GTCR, Merger, FTC, Acquisition, Litigation, Biocoat, Shareholders, Medical Devices, Regulatory Approval